<style type="text/css"> .wpb_animate_when_almost_visible { opacity: 1; }</style>

INVESTOR RELATIONS

Press Releases

Archives: Search / 2017 / 2016 / 2015 / 2014 / 2013 / 2012

2015 Archives

Nov 16, 2015
Stifel 2015 Healthcare Conference and Cannacord Genuity Medical Technologies and Diagnostics Forum
Nov 6, 2015
Interim results from a colorectal cancer study adds to the body of clinical evidence supporting Trovagene's urinary ctDNA platform for the detection and monitoring of actionable oncogene mutations using a non-invasive sample
Oct 27, 2015
Data for the detection and monitoring of EGFR T790M mutations to be presented at the AACR-NCI-EORTC International Conference
Oct 8, 2015
Consistent with prior clinical study results, non-invasive laboratory test is effective in determining mutational status
Sep 24, 2015
Quantitative detection and monitoring of circulating tumor DNA (ctDNA) and driver mutations can be used to rapidly detect treatment response
Sep 21, 2015
Data presented at the 30th International Papillomavirus Conference; general population screening trial is ongoing
Sep 10, 2015
Trovagene Research Institute aims to improve cancer care through advanced genomic solutions with the mission of accelerating adoption of Trovagene's Precision Cancer Monitoring platform in translational research and clinical applications
Sep 9, 2015
Clinical Data to be Presented in Oral Session on Liquid Biopsies at the 16th World Conference on Lung Cancer
Aug 18, 2015
Clinical data in lung, colorectal, and pancreatic cancer demonstrate the utility of Trovagene's Precision Cancer Monitoring platform as an important disease management tool
Jul 8, 2015
Study objective is to deliver a urinary liquid biopsy-based solution to provide faster and more accurate information for measuring response to immunotherapy
Jun 8, 2015
Data support the clinical utility of using the Company's Precision Cancer Monitoring technology in the management of non-small cell lung and colorectal cancers
May 28, 2015
Expanded physician access program, new awareness campaign, and clinical data presentations at ASCO highlight the Company's urine-based liquid biopsy service
May 13, 2015
Precision Cancer Monitoring technology offers advantages over tissue biopsy and demonstrates ability to monitor tumor dynamics in lung, pancreatic, and colon cancers
 

email print rss